BAZ2A: A Protein Involved in Alzheimer's Disease (G11176)

Target Name: BAZ2A

NCBI ID: G11176

BAZ2A

BAZ2A: A Protein Involved in Alzheimer's Disease

BAZ2A, also known as TIP5, is a protein that is expressed in the brain and plays a crucial role in the development and progression of several neurological disorders, including Alzheimer's disease. The protein is a key regulator of the tau protein, which is a normal protein that helps keep brain cells healthy. However, in the case of Alzheimer's disease, the levels of tau protein are abnormal and contribute to the destruction of brain cells.

Research has shown that BAZ2A is involved in the formation of beta-amyloid plaques, which are a hallmark of Alzheimer's disease. The beta-amyloid plaques are composed of abnormal aggregates of the tau protein and are thought to contribute to the neurotoxicity of the disease.

Additionally, BAZ2A has been shown to play a role in the regulation of the neurotransmitter dopamine, which is involved in mood and motivation. Imbalances in dopamine levels have been implicated in the development of mood disorders, including depression and schizophrenia.

BAZ2A is also involved in the regulation of the neurotransmitter glutamate, which is involved in learning and memory. Imbalances in glutamate levels have been implicated in the development of cognitive impairments, including Alzheimer's disease.

In addition to its role in the development and progression of Alzheimer's disease, BAZ2A is also a potential drug target. Researchers have identified several small molecules that can interact with BAZ2A and have shown that these molecules have the potential to treat Alzheimer's disease.

One of the most promising of these molecules is called BHV-3501, which is a small molecule that can inhibit the activity of BAZ2A. Preclinical studies have shown that BHV-3501 has the potential to treat Alzheimer's disease by reducing the formation of beta-amyloid plaques and improving the levels of dopamine and glutamate in the brain.

Another potential drug target for BAZ2A is a class of drugs called TAPI3 inhibitors. These drugs work by inhibiting the activity of the enzyme tyrosine phosphorylase, which is involved in the regulation of BAZ2A.

Research has shown that TAPI3 inhibitors have the potential to treat Alzheimer's disease by reducing the formation of beta-amyloid plaques and improving the levels of dopamine and glutamate in the brain.

Another approach to targeting BAZ2A is to use small molecules that can modulate the activity of the protein. For example, researchers have shown that a small molecule called 1-[(3-isothiocyanatopyrrolidin-1-yl)-(3-methoxy-4-pyrrolidin-1-yl)]-2,4-dinitrophenyl-5-L-alanine aminotransferase (ALAA) can modulate the activity of BAZ2A.

While further research is needed to fully understand the role of BAZ2A in the development and progression of Alzheimer's disease, it is clear that this protein is an important target for the development of new treatments for this debilitating and progressive disease.

Protein Name: Bromodomain Adjacent To Zinc Finger Domain 2A

Functions: Regulatory subunit of the ATP-dependent NoRC-1 and NoRC-5 ISWI chromatin remodeling complexes, which form ordered nucleosome arrays on chromatin and facilitate access to DNA during DNA-templated processes such as DNA replication, transcription, and repair (PubMed:28801535). Both complexes regulate the spacing of nucleosomes along the chromatin and have the ability to slide mononucleosomes to the center of a DNA template (PubMed:28801535). Directly stimulates the ATPase activity of SMARCA5 in the NoRC-5 ISWI chromatin remodeling complex (PubMed:28801535). The NoRC-1 ISWI chromatin remodeling complex has a lower ATP hydrolysis rate than the NoRC-5 ISWI chromatin remodeling complex (PubMed:28801535). Within the NoRC-5 ISWI chromatin remodeling complex, mediates silencing of a fraction of rDNA by recruiting histone-modifying enzymes and DNA methyltransferases, leading to heterochromatin formation and transcriptional silencing (By similarity). In the complex, it plays a central role by being recruited to rDNA and by targeting chromatin modifying enzymes such as HDAC1, leading to repress RNA polymerase I transcription (By similarity). Recruited to rDNA via its interaction with TTF1 and its ability to recognize and bind histone H4 acetylated on 'Lys-16' (H4K16ac), leading to deacetylation of H4K5ac, H4K8ac, H4K12ac but not H4K16ac (By similarity). Specifically binds pRNAs, 150-250 nucleotide RNAs that are complementary in sequence to the rDNA promoter; pRNA-binding is required for heterochromatin formation and rDNA silencing (By similarity)

The "BAZ2A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BAZ2A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets